deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03775200

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

Sponsor: COMPASS Pathways

Conditions Treatment Resistant Depression
Interventions Psilocybin
Updated 23 times since 2019 Last updated: Apr 21, 2023 Started: Mar 1, 2019 Primary completion: Jul 30, 2021 Completion: Sep 27, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Treatment Resistant Depression and is currently completed. COMPASS Pathways leads this study, which shows 23 recorded versions since 2019 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

~Jan 2019 – ~Aug 2019 · 7 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~May 2023 · 15 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

23 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. May 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Feb 2022 — May 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 18 earlier versions

  1. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  3. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  7. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  8. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  9. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  10. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  11. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  12. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  13. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  14. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  15. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  16. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  17. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  18. Jan 2019 — Aug 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • COMPASS Pathways
Data source: COMPASS Pathways

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Atlanta, United States , Baltimore, United States , Barcelona, Spain , Berlin, Germany , Bristol, United Kingdom , Dublin, Ireland , Groningen, Netherlands , Houston, United States , Klecany, Czechia and 13 more locations